The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinical trials for SONIC HEDGEHOG (SHH)-subgroup medulloblastoma (MB) patients. Clinical experience with BCC patients shows that continuous exposure to vismodegib is necessary to prevent tumor recurrence, suggesting the existence of a vismodegib-resistant reservoir of tumor-propagating cells. We isolated such tumor-propagating cells from a mouse model of SHH-subgroup MB and grew them as sphere cultures. These cultures were enriched for the MB progenitor marker SOX2 and formed tumors in vivo. Moreover, while their ability to self-renew was resistant to SHH inhibitors, as has been previously suggested, this self-renewal was instead WNT-dependent. We show here that loss of Trp53 activates canonical WNT signaling in these SOX2-enriched cultures. Importantly, a small molecule WNT inhibitor was able to reduce the propagation and growth of SHH-subgroup MB in vivo, in an ontarget manner, leading to increased survival. Our results imply that the tumor-propagating cells driving the growth of bulk SHHdependent MB are themselves WNT dependent. Further, our data suggest combination therapy with WNT and SHH inhibitors as a therapeutic strategy in patients with SHH-subgroup MB, in order to decrease the tumor recurrence commonly observed in patients treated with vismodegib.
INTRODUCTION
Medulloblastoma (MB) is the most common malignant brain tumor of childhood. 1 While the bulk of patients respond to multimodal therapy (surgery, radiation and cytotoxic chemotherapy), treatment-induced morbidity leaves survivors with significant neurocognitive and endocrine disabilities. 2 These patients thus require therapies that promise to be more effective and less toxic. The classification of MB into four molecular subgroups 3, 4 provided a template with which to begin identifying and testing such targeted therapies. 5, 6 The best characterized subgroup is driven by the SONIC HEDGEHOG (SHH) signaling pathway, most commonly via mutation and loss of the gene encoding the SHH receptor PATCHED (PTCH). The SHH inhibitor vismodegib targets the upstream signaling component SMOOTHENED (SMO) and is FDA-approved for advanced basal cell carcinoma, 7 which is almost uniformly driven by SHH signaling. 8, 9 As similar SMO inhibitors effectively target SHH-dependent mouse models of MB, significantly reducing the bulk of such tumors, 10 they are now being tested in SHH-subgroup MB patients. [11] [12] [13] Tumors are heterogeneous, comprised of immune, stromal and tumor cells proper. Even the tumor cells themselves show significant variation in morphologies, proliferation rates and selfrenewing capacity. 14, 15 This heterogeneity is thought to result from a hierarchical organization, in which a small population of relatively quiescent, long-lived, multipotent, propagating/initiating cells drives the production of a population of rapidly amplifying progenitor cells, which in turn can give rise to more differentiated cell types. 16 Although the progenitor cells constitute the bulk of the tumor, they have limited self-renewing capacity, and are thus maintained by the smaller population of tumor-propagating cells. The tumor-propagating cells are relatively chemotherapy resistant, and are therefore thought to drive the tumor recurrence often observed in patients treated with chemotherapy. 17 Similarly, while limited clinical experience with SMO inhibitors in clinical trials has shown that there is often a rapid initial response to vismodegib, this is frequently followed by aggressive recurrent MB growth. 11, 18 Additionally, it was noted that basal cell carcinoma patients often exhibited rapid recurrence upon vismodegib cessation, consistent with such tumors harboring a reservoir of vismodegib-resistant cells capable of driving recurrence. [19] [20] [21] [22] A number of tumor-propagating cells have been described for the SHH-subgroup of MB, with distinct properties, biomarkers, sensitivity to SMO inhibitors and abilities to be propagated as neurospheres ex vivo. [23] [24] [25] [26] [27] [28] Most recently, lineage tracing in a mouse model of SHH MB identified a small population of SOX2 + MB propagating cells (MPCs), and a population of SOX2 − cells that constituted the bulk of the tumor proper. 28, 29 The SOX2 + cells were capable of efficient self-renewal but resistant to vismodegib, while the SOX2 − cells exhibited a more limited capacity for selfrenewal but were sensitive to vismodegib. Consistent with this observation, treatment of this mouse model of MB with vismodegib led to an enrichment of SOX2 + cells in the residual tumor. 28 These SOX2 + cells may contribute to recurrence observed in patients treated with vismodegib. Here, we show that selfrenewal of SOX2 + enriched sphere cultures (SCs) is dependent on canonical WNT activity, and that loss of Trp53 drives this WNT dependence. A small molecule WNT inhibitor also depleted this population of SOX2 + cells in SHH-subgroup MB in vivo, significantly reducing the ability of SHH tumors to propagate.
RESULTS
Characterization of MB sphere cultures SHH-subgroup MBs harbor a small and phenotypically primitive population of MPCs that are enriched in cultured neurospheres ex vivo. 25, 27 We isolated and characterized the MPC-like characteristics of three independent Ptch1 −/− -;Trp53 −/− neurosphere cultures (SC 1-3). These cultures were enriched for neural stem cell markers, such as Nestin and Sox2, relative to bulk MB tissue (Figure 1a) . They also displayed the cellular heterogeneity previously described for MPCs enriched cultures, 25, 30 as evidenced by the mutually exclusive staining of a neural stem cell marker (NESTIN) with that of a neuronal progenitor marker (β3-TUBULIN) ( Figure 1b) . The SCs could be induced to express biomarkers of three distinct neural lineages (Figure 1c ), suggesting that they are also pluripotent. Consistent with them being enriched for tumorpropagating cells, as few as 5000 SC cells were able to form tumors when implanted into mice (Figure 1d ). SOX2 has previously being described as a biomarker for such tumorpropagating cells. 28, 29 We therefore quantitated the percentage of SOX2 + cells in the SCs relative to that in primary MB tissue. SOX2 + cells were considerably more enriched in the SCs, relative to the approximate 5% of such cells observed in primary MB (Figure 1e ).
The self-renewal of MPCs is dependent on WNT activity The MPC enriched SCs were exposed to the SMO inhibitors cyclopamine and vismodegib, the inactive cyclopamine analog tomatidine, or a vehicle control. Interestingly, even though the parental MB tissue responded to vismodegib in vivo (Supplementary Figure S1A) , neither SMO inhibitor had significant effects on the cellular viability (Supplementary Figures S1B,C 27 Further, SOX2 expression, for which the SCs are enriched (Figure 1e ), is WNT-dependent in many physiological settings. 31 Thus, we hypothesized that the MB SCs we had isolated were WNT-dependent. Consistent with this hypothesis, SCs were enriched for WNT signaling biomarkers relative to primary MB (Figure 2a ). To directly test whether SCs are WNT-dependent we transfected them with pools of siRNA targeting the pivotal WNT signaling component β-Catenin (Ctnnb1), green fluorescent protein (GFP), or a scrambled control siRNA. Relative to the control siRNAs, the Ctnnb1 siRNA reduced the expression of the WNT biomarker Lgr5 as well as Sox2, but had no effect on the SHH target genes Gli1 or Ptch2 (Figure 2b) . Further, the Ctnnb1 siRNA attenuated the self-renewal capability of the SCs (Figure 2c ), but had little effect on the overall viability of these cultures (Supplementary Figure S2A) . Although WNT activation in MB is commonly linked to Ctnnb1 mutations, 32, 33 no Ctnnb1 mutations were identified in the SCs (Supplementary Figure S2B) . As β-CATENIN also plays an essential role in E-CADHERIN signaling, distinct from its role in WNT signaling, 34 we also utilized a dominant negative form of the WNT transcription factor TCF3 (dnTCF3) commonly used to definitively identify WNT-dependent biomarkers. 35 Cultures expressing dnTCF3 exhibited significantly attenuated WNT target gene expression, including Sox2, but had no effect on the expression The ability of SC-2 to form secondary spheres was determined 48 h after transfection with a dnTCF3 expression plasmid or control plasmid (pCS2). (f) SC-2 was transfected with a plasmid expressing a dnTCF3 construct or control plasmid (pCS2) and cell viability determined 5 days later using an MTT reduction assay. (g) SC-2 was transfected with a plasmid expressing DKK1 or control plasmid (pCS2) and the expression of WNT target genes determined. (h) The ability of SC-2 to form secondary spheres was determined 48 h after transfection with a plasmid expressing DKK1 or control plasmid (pCS2). (i) SC-2 was transfected with a plasmid expressing DKK1 or control plasmid (pCS2) and cell viability determined 5 days later using an MTT reduction assay. Results were normalized to that from pCS2 transfected cultures unless otherwise indicated. MTT, 3-(4,5-dimethyl-2-thiazolyl) 2,5-diphenyl-2H-tetrazolium bromide.
of two SHH target genes (Figure 2d ). SCs expressing dnTCF3 had a reduced capacity for self-renewal (Figure 2e ), but exhibited no change in viability (Figure 2f ). To examine if the WNT activation we observe in SCs is ligand-driven we overexpressed a negative regulator of the canonical WNT pathway, DKK1, which antagonizes the LRP5/6 WNT co-receptor. 36 Overexpression of DKK1 downregulated WNT target gene expression (Figure 2g ), and reduced secondary sphere formation ( Figure 2h ) without affecting cell viability (Figure 2i ). Combined, these results suggest that WNT signaling plays an important role in the self-renewal of the SCs, but a more minimal role in the immediate viability of these cultures. Consistent with this suggestion, two small-molecule activators of WNT signaling (GSK-3β inhibitors) 37 significantly increased the self-renewal capacity of these SCs (Supplementary Figure S2C) .
Small-molecule WNT inhibitors attenuate the self-renewal of MPCs To identify a small-molecule WNT inhibitor that could be used to attenuate MB growth in vivo, we screened a number of mechanistically distinct small-molecule WNT inhibitors for their ability to attenuate self-renewal ex vivo. As downregulation of WNT signaling by DKK1 overexpression reduced secondary sphere formation (Figure 2h ), and DKK1 acts to suppress liganddependent WNT signaling, 36 we tested a small-molecule that directly attenuates WNT ligand activity, the PORCUPINE inhibitor LGK974. 38 Similar to DKK1 overexpression, PORCUPINE inhibition reduced WNT pathway activation ( Figure 3a ) and secondary sphere formation (Figure 3b ), without affecting SC viability (Figure 3c ). Consistent with this WNT activation being ligand driven, Wnt7a and Wnt7b were highly expressed in SCs relative to parental MB tissue (Supplementary Figure S3A) .
As both Ctnnb1 knockdown (Figure 2c ) and overexpression of dnTCF reduced secondary sphere formation (Figure 2e ), we included in our screening antagonists of the TCF/β-CATENIN complex: carnosate, 39 CCT-031374, 40 ICG-001 41 and PKF115-584. 42 We first confirmed that this panel of TCF/β-CATENIN antagonists reduced WNT activity in a WNT-dependent reporter assay (Supplementary Figure S3B) . We next treated SCs with these antagonists and observed a significant reduction in secondary sphere formation (Figure 3d) , which occurred at lower doses than those that had effects on SC viability (Figure 3e ). These WNT inhibitors also attenuated the expression of WNT target genes in SCs (Figure 3f ), consistent with an on-target mechanism of action. We also verified that one of these inhibitors, carnosate, reduced the expression of Sox2 (Supplementary Figure S3C) and the numbers of SOX2 + cells in these cultures (Supplementary Figure S3D) . Figure S3F) . Together, these results are consistent with WNT signaling controlling Sox2 expression, which is required for SCs to self-renew.
Loss of Trp53 results in WNT-dependent self-renewal A number of groups have previously shown that WNT activation attenuates SHH-subgroup MB growth, [43] [44] [45] observations inconsistent with our results. These previous results were obtained using SmoA1-or Ptch1-driven MB mouse models, or cells derived from such mice, which in all cases were in a wild type (WT) Trp53 background. Thus, we hypothesized that the WNT requirement for SC self-renewal that we observe results from loss of Trp53. To test this hypothesis, we compared the expression of WNT biomarkers in Ptch1 −/− SCs expressing WT Trp53 or deficient for Trp53. We noted that expression of WNT biomarkers, including WNT ligands, was significantly reduced in the SCs expressing WT Trp53 (Figure 4a ). SCs expressing WT Trp53 were unresponsive to small-molecule β-CATENIN/TCF inhibitors, as carnosate was unable to downregulate the expression of WNT target genes (Figure 4b ), attenuate self-renewal (Figure 4c ) or affect viability (Figure 4d) . Further, overexpression of dnTCF3 did not attenuate WNT target gene expression (Figure 4e ) or self-renewal (Figure 4f ) in WT Trp53 SCs, but did in Trp53-deficient cultures. The cell viability of either SC was not reduced by dnTCF3 (Supplementary Figure S4A) . To more directly address the effects of P53 on WNT signaling we attenuated P53 activity in SCs expressing WT Trp53 and expressed WT Trp53 in those cultures deficient in Trp53, and determined P53 and WNT activity. We observed increased expression of a P53 target gene (Mdm2) and decreased expression of WNT target genes upon transfection of Ptch1 −/− SCs deficient in Trp53 with a plasmid expressing WT Trp53 (Figure 4g) . Conversely, reducing P53 activity in Ptch1 −/− SCs WT for Trp53, via expression of a dominant negative Trp53 construct or treatment with the smallmolecule P53 inhibitor [Pifithrin-α (PFTα)], reduced Mdm2 expression but increased expression of WNT target genes (Figures 4h  and i) . Together, these results suggest that loss of Trp53 results in increased WNT activity in Ptch1 mutation-driven SCs.
MB growth and propagation is WNT-dependent
To examine the dependence of MB growth and initiation on WNT signaling in vivo, we implanted Trp53 mutant, Ptch1-driven MB 
;Trp53
+/+ SCs were incubated with the P53/MDM2 inhibitor Pifithrin-α (PFT-α) for 24 h, and the expression of the indicated genes determined. The results were normalized to those from the dimethyl sulfoxide control. MTT, 3-(4,5-dimethyl-2-thiazolyl) 2,5-diphenyl-2H-tetrazolium bromide.
tissue, which had never been cultured ex vivo, into the brains of immunocompromised mice and treated them with vehicle or carnosate. Carnosate was selected for these in vivo studies based on ex vivo efficacy and its blood brain barrier penetrance. 46 These mice were treated for 20 days, or until they displayed behavior consistent with having MB (head tilt, hunched posture, ataxia, weight loss), at which time the mice were killed and their brains collected for further analyses. We noted that orthotopically grown MBs were significantly smaller in carnosate treated mice relative to vehicle treated mice (Figures 5a and b) . These smaller residual tumors had decreased numbers of proliferating cells, as determined by PCNA immunostaining (Figure 5c, Supplementary  Figure S5A) , and decreased numbers of SOX2 + cells (Figure 5d,  Supplementary Figure S5B) . These results appear distinct from our ex vivo experiments in which carnosate did not affect culture growth (Figure 3e, Supplementary Figure S3F) . We speculate that the effects we see on MB cell proliferation in vivo are indirect, resulting from loss of the MPCs that drive bulk tumor growth. Likely, similar effects were not observed ex vivo because of the significantly reduced time such cultures were exposed to carnosate.
To determine the WNT dependence of MPCs in vivo, we implanted MB tissue into the flanks of mice and treated them with carnosate or vehicle once tumor growth was palpable. Carnosate significantly reduced the expression of WNT target genes, but not SHH target genes, in these tumors (Figure 5e) , and reduced the numbers of SOX2 + cells (Figure 5f , Supplementary Figure S5C ). Consistent with carnosate treatment reducing the number of MPCs, MB tissue from the carnosate-treated primary tumors also displayed significantly reduced ability to initiate new tumors when similar numbers of viable donor cells were reimplanted into recipient mice (Figure 5g) . We also reimplanted carnosate-treated MB tissue from donor mice orthotopically into naïve recipient mice, and monitored their MB symptom-free survival. Consistent with carnosate treatment reducing MB propagation, mice harboring carnosate-treated tumor tissue exhibited significantly increased MB symptom-free survival over those that received MB tissue from vehicle-treated donors (Figure 5h ). 
DISCUSSION
The WNT signaling pathway regulates multiple aspects of stem cell function. Indeed, WNT ligands play key roles in neuronal stem cell self-renewal, 31 symmetric division, 47 pluripotency 48 and tumor initiation in cancer stem cells. 31, 49 We show here that the selfrenewal of multipotent, SOX2 + -enriched SCs, which ultimately drive the growth of Trp53-deficient SHH-subgroup MB, is dependent on WNT activity. This conclusion is based on inhibiting several components of the canonical WNT signaling pathway, using both molecular genetic and small-molecule inhibitors (Supplementary Figure S6) . Further, we show that a smallmolecule WNT inhibitor is able to reduce the number of SOX2 + cells, tumor initiation and tumor growth in vivo, increasing the overall survival of mice harboring Trp53-deficient SHHsubgroup MB.
Our Trp53-deficient SCs had reduced expression of SHH biomarkers relative to primary MB tissue, which is likely why they were resistant to SMO inhibitors. 50 However, these cultures expressed both WNT ligands and biomarkers associated with an activated WNT signaling pathway. Consistent with MPC selfrenewal being WNT ligand-dependent, a PORCUPINE inhibitor, which reduces WNT ligand activity, 38 or overexpression of DKK1, which attenuates WNT co-receptor activation, 36 prevented SCs self-renewal. The self-renewal of Trp53-deficient SCs also required canonical β-CATENIN/TCF activity, as knockdown of β-Catenin, overexpression of dnTCF3, or four distinct small-molecule inhibitors of this WNT-dependent transcriptional complex, inhibited self-renewal. Based on the sensitivity of these cultures to these mechanistically distinct small molecule and molecular genetic regulators of WNT signaling, we suggest that the MPC-enriched cultures elaborate a WNT ligand-dependent activation of canonical β-CATENIN/TCF signaling, which ultimately drives SC self-renewal.
It was previously suggested that WNT signaling attenuates the growth of SHH-subgroup MB. [43] [44] [45] This work showed that the repressive effect of WNT activity on SHH-subgroup MB was indirect, via downregulation of SHH signaling. The major difference between these previous studies and our work is that we use a Trp53-deficient mouse model of MB. Consistent with this previous work, we show that SCs expressing WT Trp53 do not express high levels of WNT biomarkers, are not sensitive to WNT inhibition and do not self-renew in a WNT-dependent manner. However, we also show that reducing P53 activity in these WT Trp53 cultures increased WNT activity and that overexpression of Trp53 in Ptch1 −/− ;Trp53 −/− SCs reduced WNT activity. Together, these results suggest that loss of Trp53 expression modulates the WNT dependence of Ptch1 mutant-driven MB. Similarly, it was previously suggested that P53 can repress canonical WNT signaling in several tumor types. In some tumors, such as neuroblastoma and breast cancer, this regulation was shown to occur via the transcriptional activation of specific micro-RNAs. 51, 52 While in colorectal cancer, loss of TRP53 activates WNT signaling via BONE MORPHOGENIC PROTEIN signaling.
53
TRP53 status is the most important risk factor of SHH-subgroup MB patients. 13, 54, 55 These patients, who tend to be children with germline TRP53 mutations, exhibit a significantly reduced 5-year survival rate. 56 Further, clinical trials of vismodegib noted reduced progression-free survival of SHH-subgroup MB patients deficient in P53 activity. 13 Our findings suggest a model in which loss of Trp53 results in the emergence of a vismodegib resistant, WNTdependent population of MPCs. We further suggest that this population of WNT-dependent MPCs might underlie the poor outcome and relative vismodegib resistance of SHH-subgroup patients deficient in TRP53. Indeed, a similar model in which WNTdependent basal cell carcinoma propagating cells drive bulk SHHdependent basal cell carcinoma growth has been described. 57, 58 Although the translational relevance of our findings using mouse models of MB are not yet known, we speculate that a therapeutic approach using WNT inhibitors would improve the outcome of TRP53-deficient SHH-subgroup patients. Importantly, such patients would likely benefit most from the use of combination therapy that also includes conventional chemotherapy or one of the SMO inhibitors now in clinical trials. Such a therapeutic strategy would inhibit the growth of the bulk tumor by targeting the rapidly dividing MB cells as well as target the MPCs that are resistant to such agents. 59 
MATERIALS AND METHODS
MPC enrichment and assay MB tissue was enzymatically and mechanically digested using the Papain Dissociation System (Worthington, Lakewood, NJ, USA). 60, 61 The resulting cell suspensions were grown ex vivo in Neurobasal serum-free medium containing 1% Glutamax, 2% B27, 1% N2, epidermal growth factor (25 ng/ ml), fibroblast growth factor (25 ng/ml) and Pen-Strep (Invitrogen, Frederick, MD, USA) and allow to form spheres for up to 10 days. For analysis by immunocytochemistry, SCs were plated on poly-L-lysine-coated glass chamber slides (Millipore, Billerica, MA, USA) in the medium described above or in Neurobasal medium containing 2% fetal bovine serum for 6 days, essentially as previously described. 62 
Cell and molecular biology
Plasmids expressing a dominant-negative TCF3 construct (dnTCF3), 63 DKK1 (Addgene, Cambridge, CA, USA), Trp53 (Takara, Mountain View, CA, USA), a dominant-negative P53 (dnTrp53) (Takara) or siRNA smart pools (Dharmacon, Lafayette, LA, USA) were transfected into SCs using Lipofectamine 2000 (Invitrogen). Cell viability was monitored by the reduction of 3-(4,5-dimethyl-2-thiazolyl) 2,5-diphenyl-2H-tetrazolium bromide to formazan, 64 or by trypan blue exclusion when evaluating the number of viable cells prior to sphere formation assays, FACS analysis or engraftment in vivo. Secondary sphere formation was determined using equal numbers of viable cells, from treated primary SCs, to form spheres in 8 days. Total RNA was Trizol (Invitrogen) extracted and the expression of the indicated genes determined using quantitative real-time PCR (RT-qPCR) and Taqman probes (Invitrogen), followed by normalization to the expression of Gapdh. 65 The efficacy of WNT antagonists was validated using a mycoplasma tested cell line and containing a TCF/LEF luciferase reporter gene, HEK 293 STF (ATCC, Manassas, VA, USA), treated with 10 mM LiCl and 10 mg/ml WNT3a, and normalized to protein concentration. For Ctnnb1 sequencing cDNA was prepared from total RNA extracted from SCs-1, 2, 3. The region of β-Catenin (Ctnnb1) encoding exon 3 was sequenced and compared to WT. Primer sequences used were Ctnnb1 Fw: 5′-CGC TGCGTGGACAATGGCTA-3′ and Ctnnb1 Rv: 5′-CGTGTGGCAAGTTCCGCGTC -3′. Sequence alignment was performed using Ape software.
Mouse work
All mouse work was conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee at the University of Miami. Ptch1 tm1Mps /J 66 and B6.129S2-Trp53 tm1Tyj /J 67 mice (Jackson laboratory, Bar Harbor, ME, USA) were mated to generate a breeding colony.
Spontaneous tumors Ptch1
−/− ;Trp53 +/+ implant 10 000 viable cells for symptom-free survival studies. For flank treatments, 1 000 000 viable cells were subcutaneously implanted into 6-week-old male CD1-Foxn1 nu mice and treatment started once the tumors reached a size of approximately 200 mm 3 . Mouse tissues were fixed in formalin prior to be stained. For in vivo engraftment studies, the indicated numbers of viable cells from residual tumors were implanted into the flanks of 6-week-old male CD1-Foxn1 nu mice. For all in vivo studies, 50 μl of 50 mg/kg vismodegib (Selleckchem, Houston, TX, USA) or 10 mg/kg carnosate (Enzo, Farmingdale, NY, USA) both dissolved in dimethyl sulfoxide and were administrated daily via intra-peritoneal injection.
Statistical analysis
For our ex vivo analyses, the results shown represent the mean of at least three independent experiments ± s.e.m. For in vivo analyses, the results shown represent the mean and s.e.m. of at least six mice. For IHC quantification, the results shown represent the mean and s.e.m. of at least six fields from three different tumors. Sample sizes were chosen based on similar well-characterized experiments to ensure adequate power to detect a pre-specified effect size. Mice were randomly distributed to different treatments and the investigator blinded to the assignment until final tumor analyses. For symptom-free survival analysis, those mice that did not show tumors as per hematoxylin eosin staining 60 days after experiment initiation were excluded from the analyses. Significance in multiple group comparisons was determined using a one-way analysis of variance followed by a post-hoc Student-Newman-Keuls analysis. Two sample analyses were determined using a one-tailed Student's t-test. Data generated showed normal distribution with similar variances, and analysis was completed assuming equal variances. Statistical significance was reached when Po 0.05. The significance of tumor frequency was determined using a χ 2 test, and statistically significance determined when αo0.05. Survival significance was calculated using a Log-rank (MantelCox) test and statistically significance reached when Po0.05.
